Gene Biotherapeutics, Inc.
Gene Biotherapeutics, Inc. (CRXM) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0000772320 · CRXM · OTC · as of Jun 9, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0000772320 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Gene Biotherapeutics, Inc. (OTC: CRXM) has submitted 546 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2000. As a Healthcare sector company with CIK 0000772320, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Gene Biotherapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Gene Biotherapeutics, Inc. 10-K was filed on 2022-04-14 for fiscal year ending 2022. Historical CRXM 10-K annual reports are available from 1996 through 2022.
Investors researching Gene Biotherapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
CRXM SEC Filings · 8 questionsGene Biotherapeutics, Inc. (CRXM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 546 filings and access original documents at no cost. Gene Biotherapeutics, Inc.'s CIK is 0000772320.